Urological Research Foundation's home page
About the Urological Research Foundation
Prostate Cancer Questions & Answers
Quest Newsletter Articles
Past Quest Publications
Media articles and interviews with Dr. Catalona
Dr. Catalona's journal articles from various publications
Dr. Catalona's genetic research for prostate cancer
Dr. Catalona's genetic research for prostate cancer
Donate to the URF for prostate cancer research
View the New Patient Packet sent by Dr. Catalona
Post-Op Advice for patients
Contact the Urological Research Foundation

Dr. Catalona and the URF appreciate and need your support for their livesaving mission to support research and patient education in prostate cancer. Please consider a generous tax-deductible donation.



Click here
to watch video


Sign up for URF emails

The site for prostate cancer information
from Dr. William Catalona

William J. Catalona, MD
William J. Catalona, MD © photo by Cissy Lacks

Our goal is to provide information on the latest advances in prostate cancer treatment and information on the research and work of Dr. William J. Catalona, Medical Director of the Urological Research Foundation (URF).

Dr. Catalona developed the PSA test as a screening test for prostate cancer. He and his research collaborators continue their important work.

The funds and energies of the Urological Research Foundation (URF) are directed to research for the prevention, detection, treatment and cure of the diseases of the prostate and most specifically, prostate cancer.

Dr. Catalona is one of the first surgeons to perform and perfect nerve sparing surgery in radical prostatectomy operations. Dr. Catalona has performed more than 6,000 radical prostatectomies.


Early Treatment of Prostate Cancer

Early Treatment of Prostate Cancer

The Early Treatment of Prostate Cancer video explains the issues associated with the treatment of early prostate cancer. This video is for men who have been recently diagnosed with prostate cancer and are trying to weigh the various treatment options.

Watch the video.

Learn more:

WGN News Features PHI Test

The Prostate Health Index (PHI) test is now available at Northwestern Memorial Hospital, offering patients a new option for detecting prostate cancer. In February, WGN News highlighted the PHI test and interviewed Dr. Catalona in a story entitled “New test means new way to fight prostate cancer.”

Watch the WGN feature story here.

Alert: New Concerns Revealed about Robotic Surgery

FDA Surveying Hospitals and Surgeons about Robotic Surgery Complications

The FDA is investigating the safety of surgical robots used in many US hospitals for surgery. By surveying surgeons at key hospitals, the government agency seeks to determine if the rise in incidents, including deaths, reported to the FDA result from the robots or from other issues.

Learn more:

Growing Concerns About Surgical Robots

A CNBC Investigations, Inc. review reveals a rise in lawsuits and complaints about injuries after da Vinci surgical robot procedures.

Learn more:

Relevant QUEST Articles:

Cancer Detection Tool Saves Lives

The Large Urology Group Practice Association (LUGPA) released its prostate cancer screening guidelines in response to the recent PSA controversy, saying that data clearly demonstrates that are detecting prostate cancer earlier and thus saving lives.

The LUGPA's position on PSA screening is:

  • Risks of prostate cancer screening must be uncoupled from risks of prostate cancer detection and treatment
  • PSA testing facilitates the early detection of prostate cancer, which results in a reduced risk of being diagnosed with or developing locally advanced and/or metastatic prostate cancer, and a reduction in prostate cancer-specific mortality
  • A baseline PSA level should be obtained in men in their 40s who have made an informed decision to pursue early detection of prostate cancer
  • Intervals for an individual's prostate cancer screening should be adapted to: baseline PSA, prostate cancer risk factors (including African-American heritage and a family history of prostate cancer), and the potentially short preclinical timeline of aggressive cancers
  • PSA screening should be offered to men with a life expectancy of greater than or equal to 10 years, regardless of age
  • PSA testing should not be considered on its own, but rather as part of a multivariable approach to early prostate cancer detection

LUGPA is an organization advocating for integrated and coordinated urological care with more than 2,000 physician experts across the U.S. The association represents 121 large urology group practices in the United States, with more than 2,000 physicians who make up more than 20% of the nation’s practicing urologists.

International Prostate Cancer Research Group Receives Funding

The International Consortium for Prostate Cancer Genetics (ICPCG) received a grant for its important genetic research. Specifically, the ICPCG whole exome sequence project will receive funding. The results of this project could be incorporated in Dr. Catalona’s SPORE (Specialized Program of Research Excellence) proposal to discover genetic variants associated with the aggressive types of prostate cancer that lead to the failure of active surveillance.

The ICPCG is a collaborative group conducting research on familial prostate cancer. The researchers in this group share a common interest in genetic susceptibility for prostate cancer. Dr. Catalona is a principal investigator of the Northwestern University site of the ICPCG.

Learn more about the ICPCG here.

Responding to USPSTF Recommendation

Family of ducks.
© photo by Dan Oldfield Not all things that look alike behave alike.

Click to see articles and material.

This section includes articles to help you understand the disturbing ramifications of the recent USPSTF recommendation on PSA testing, the misinterpretation of studies, and what can be done to ensure men have a choice in taking the test. We also provide information on contacting your government representatives.

"PSA is the best screening test we have for prostate cancer, and until there is a replacement for PSA, it would be unconscionable to stop it. Contrary to the USPSTF report, compelling evidence shows that PSA screening reduces prostate cancer deaths. This evidence needs to be shared with the public."
–Dr. Catalona
Healthcare decisions are as much about the future as the present, and they need to be based upon accurate and reliable information.

Participate in Research Studies

Northwestern Memorial Hospital and Dr. William Catalona offer opportunities for you to participate in research projects on the treatment and prevention of prostate cancer.

Learn more here.


Dr. Catalona in surgurey

Dr. Catalona: Over 6,000 Operations

Dr. Catalona is celebrating a surgical anniversary. He has now performed more than 6,000 radical prostatectomies, more than anyone else in the world. Dr. Catalona is one of the first surgeons to perform and perfect nerve- sparing surgery in radical prostatectomy operations. His patients have come from all 50 states in the United States, as well as from Asia, Europe, the Middle East, and Central and South America.

High Ranking For Northwestern’s Department of Urology
The National Institutes of Health (NIH) ranks individual departments within medical schools. The Department of Urology ranked third nationally among urology departments.


Contact Dr. Catalona

William J. Catalona, M.D.
Professor, Department of Urology
Northwestern University Feinberg School of Medicine
Director, Clinical Prostate Cancer Program
Robert H. Lurie Comprehensive Cancer Center
Northwestern Memorial Hospital
675 North St. Clair Street
Suite 20-150
Chicago, Illinois 60611

Phone: (312) 695-4471
FAX (312) 695-7030
To schedule surgery, please contact
Dr. Catalona at (312) 695-6126 or via email at
wcatalona@nmff.org or wcatalona@aol.com.
Scheduling a return appointment: (312) 695-6126
E-mail: wcatalona@nmff.org



Home    |    About the URF   |    Q & A - Prostate Cancer   |    Quest Articles
Journal Articles   |    National Media   |    Genetic Research   |    Donations
New Patient Packet   |    Post-Op Advice   |    Contact Us   |    Terms & Conditions